169 related articles for article (PubMed ID: 29691978)
1. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort.
Blix K; Gran OV; Severinsen MT; Cannegieter SC; Jensvoll H; Overvad K; Hammerstrøm J; Tjønneland A; Naess IA; Braekkan SK; Rosendaal FR; Kristensen SR; Hansen JB
J Thromb Haemost; 2018 Jul; 16(7):1327-1335. PubMed ID: 29691978
[TBL] [Abstract][Full Text] [Related]
2. The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort.
Gade IL; Braekkan SK; Naess IA; Hansen JB; Cannegieter SC; Overvad K; Jensvoll H; Hammerstrøm J; Blix K; Tjønneland A; Kristensen SR; Severinsen MT
J Thromb Haemost; 2017 Aug; 15(8):1567-1575. PubMed ID: 28585779
[TBL] [Abstract][Full Text] [Related]
3. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality.
Ay C; Posch F; Kaider A; Zielinski C; Pabinger I
J Thromb Haemost; 2015 Mar; 13(3):390-7. PubMed ID: 25529107
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
Cohen AT; Katholing A; Rietbrock S; Bamber L; Martinez C
Thromb Haemost; 2017 Jan; 117(1):57-65. PubMed ID: 27709226
[TBL] [Abstract][Full Text] [Related]
5. Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.
Königsbrügge O; Posch F; Riedl J; Reitter EM; Zielinski C; Pabinger I; Ay C
Oncologist; 2016 Feb; 21(2):252-7. PubMed ID: 26764252
[TBL] [Abstract][Full Text] [Related]
6. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality.
Riedl J; Posch F; Königsbrügge O; Lötsch F; Reitter EM; Eigenbauer E; Marosi C; Schwarzinger I; Zielinski C; Pabinger I; Ay C
PLoS One; 2014; 9(10):e111440. PubMed ID: 25347577
[TBL] [Abstract][Full Text] [Related]
7. Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer.
Giustozzi M; Curcio A; Weijs B; Field TS; Sudikas S; Katholing A; Wallenhorst C; Weitz JI; Martinez C; Cohen AT
Thromb Haemost; 2020 May; 120(5):847-856. PubMed ID: 32369855
[TBL] [Abstract][Full Text] [Related]
8. Venous Thromboembolism Recurrence in Latvian Population: Single University Hospital Data.
Ģībietis V; Kigitoviča D; Strautmane S; Meilande K; Kalējs VR; Zaičenko A; Maķe K; Lejnieks A; Skride A
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31438542
[No Abstract] [Full Text] [Related]
9. A high Gas6 level in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly: a prospective multicenter cohort study.
Schnegg-Kaufmann A; Calzavarini S; Limacher A; Mean M; Righini M; Staub D; Beer JH; Frauchiger B; Osterwalder J; Kucher N; Matter CM; Husmann M; Banyai M; Aschwanden M; Mazzolai L; Hugli O; Nagler M; Daskalakis M; Rodondi N; Aujesky D; Angelillo-Scherrer A
J Thromb Haemost; 2019 Feb; 17(2):306-318. PubMed ID: 30570809
[TBL] [Abstract][Full Text] [Related]
10. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study.
Eischer L; Kammer M; Traby L; Kyrle PA; Eichinger S
J Thromb Haemost; 2017 Jul; 15(7):1368-1374. PubMed ID: 28407356
[TBL] [Abstract][Full Text] [Related]
11. Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism.
Gran OV; Braekkan SK; Paulsen B; Skille H; Rosendaal FR; Hansen JB
J Thromb Haemost; 2017 Jul; 15(7):1361-1367. PubMed ID: 28440069
[TBL] [Abstract][Full Text] [Related]
12. Red cell distribution width is associated with incident venous thromboembolism (VTE) and case-fatality after VTE in a general population.
Ellingsen TS; Lappegård J; Skjelbakken T; Brækkan SK; Hansen JB
Thromb Haemost; 2015 Jan; 113(1):193-200. PubMed ID: 25274492
[TBL] [Abstract][Full Text] [Related]
13. Unprovoked venous thromboembolism and subsequent cancer risk: a population-based cohort study.
Sun LM; Chung WS; Lin CL; Liang JA; Kao CH
J Thromb Haemost; 2016 Mar; 14(3):495-503. PubMed ID: 26748492
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study.
Douce DR; Holmes CE; Cushman M; MacLean CD; Ades S; Zakai NA
J Thromb Haemost; 2019 Dec; 17(12):2152-2159. PubMed ID: 31423717
[TBL] [Abstract][Full Text] [Related]
15. Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.
Riedl J; Kaider A; Marosi C; Prager GW; Eichelberger B; Assinger A; Pabinger I; Panzer S; Ay C
Thromb Haemost; 2017 Jan; 117(1):90-98. PubMed ID: 27761580
[TBL] [Abstract][Full Text] [Related]
16. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes.
Shaw JR; Douketis J; Le Gal G; Carrier M
J Thromb Haemost; 2019 Jul; 17(7):1171-1178. PubMed ID: 31038838
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism and subsequent permanent work-related disability.
Braekkan SK; Grosse SD; Okoroh EM; Tsai J; Cannegieter SC; Naess IA; Krokstad S; Hansen JB; Skjeldestad FE
J Thromb Haemost; 2016 Oct; 14(10):1978-1987. PubMed ID: 27411161
[TBL] [Abstract][Full Text] [Related]
18. Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
Robertson L; Yeoh SE; Broderick C; Stansby G; Agarwal R
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010837. PubMed ID: 30407621
[TBL] [Abstract][Full Text] [Related]
19. Recurrence and mortality after first venous thromboembolism in a large population-based cohort.
Arshad N; Bjøri E; Hindberg K; Isaksen T; Hansen JB; Braekkan SK
J Thromb Haemost; 2017 Feb; 15(2):295-303. PubMed ID: 27943560
[TBL] [Abstract][Full Text] [Related]
20. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients.
Mauracher LM; Posch F; Martinod K; Grilz E; Däullary T; Hell L; Brostjan C; Zielinski C; Ay C; Wagner DD; Pabinger I; Thaler J
J Thromb Haemost; 2018 Mar; 16(3):508-518. PubMed ID: 29325226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
